Article Information
History
- September 21, 2020.
Article Versions
- Version 1 (April 24, 2020 - 02:09).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Massimo Lazzeri, MD-PhD1,*,†,
- Stefano Duga, PhD1,2,*,†,
- Elena Azzolini, MD1,
- Vittorio Fasulo, MD1,
- Nicolò Buffi, MD1,2,
- Alberto Saita, MD1,
- The Humanitas COVID-19 Task Force1,
- The Humanitas Gavazzeni COVID-19 Task Force3,
- Rodolfo Hurle, MD1,
- Alessandro Nobili, MD4,
- Maurizio Cecconi, MD-PhD1,2,
- Paolo Casale, MD1 and
- Rosanna Asselta, PhD1,2
- 1Humanitas Clinical and Research Center – IRCCS –, via Manzoni 56, 20089 Rozzano (Mi) – Italy
- 2Humanitas University, Department of Biomedical Sciences, Via Rita Levi Montalcini 4, 20090 Pieve Emanuele – Milan, Italy
- 3Humanitas Gavazzeni-Castelli, Bergamo, Italy
- 4Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri, 2, 20156, Milan
- ↵*
Corresponding Authors:
Massimo Lazzeri, MD, PhD, Department of Urology, Istituto Clinico Humanitas IRCCS, Via Manzoni 56 (20089) Rozzano – Milan (Italy) Email: massimo.lazzeri{at}humanitas.it, Stefano Duga, PhD, Department of Biological Sciences, Humanitas University, Via Rita Levi Montalcini 4 (20090) Pieve Emanuele - Milan (Italy) Email: stefano.duga{at}hunimed.eu
↵* Equally contributed
Posted September 21, 2020.
Impact of anti-androgen therapies on COVID-19 susceptibility: a case-control study in male population from two COVID-19 regional centers of Lombardy (Italy)
